Philadelphia Pharmaceuticals Industry Company PSC

The company maintains a relatively strong liquidity position, with a current ratio of 2.57, indicating that it has more than twice as many current assets as current liabilities. However, its operating cash flow is negative at -97,350 JOD, and free cash flow is also negative at -244,150 JOD, suggesting that the company is currently spending more cash than it is generating from operations. The debt-to-equity ratio of 0.19 indicates a conservative capital structure, with total liabilities accounting for a small portion of total equity.

Profitability metrics show a return on equity (ROE) of 1.57% and a return on assets (ROA) of 1.17%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The company's net income of 194,740 JOD is derived from a gross profit of 1,027,390 JOD, with an operating income of 335,240 JOD. These figures suggest that while the company is profitable, its margins are relatively modest compared to industry benchmarks.

The company's revenue is concentrated in a single business segment, as no additional segments are disclosed in the available data. There is no information provided on geographic revenue distribution, but the company's primary operations are likely centered in the region where it is incorporated. This lack of diversification may expose the company to higher operational and market risks.

The company's growth trajectory is not clearly defined in the available data, as no specific revenue growth rates or future projections are provided. However, the negative operating and free cash flows suggest that the company may be investing in long-term projects or facing operational challenges that could impact its near-term growth.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key liquidity flag is the negative net cash position after subtracting total debt, which could limit the company's ability to fund operations or invest in growth opportunities without external financing. The low dilution risk indicates that the company is not currently issuing a large number of new shares, which helps preserve shareholder value.

There are no recent events or filings disclosed in the available data that would significantly impact the company's operations or financial position. The absence of recent transcripts or regulatory filings suggests a relatively stable and uneventful period for the company.

Net income surged 22.4% year-over-year to JOD 1.0 million, demonstrating strong profitability growth momentum.

Free cash flow rebounded sharply by 423.2% to JOD 796,220, reversing the previous year's negative cash flow position.

Revenue grew at an impressive 8.6% compound annual growth rate over the last four fiscal years.

Net margin of 8.6% outperforms the industry median of 4.1%, highlighting effective cost management relative to peers.

Cash conversion ratio sits in the bottom quartile at -0.5, significantly worse than the cohort median of 0.96.

The company faces medium liquidity risk, which could constrain short-term financial flexibility and operational stability.

Medium credit risk flags potential challenges in debt servicing or broader financial health stability for investors.

Return on assets of 1.2% remains low, indicating limited efficiency in generating profits from total asset base.